HR+/HER2 Breast Cancer Palbociclib: Effective, simple, and safe

被引：0
|
作者：
Sonnet, Miriam
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF PALBOCICLIB PLUS LETROZOLE IN THE TREATMENT OF HR+/HER2-ADVANCED OR METASTATIC BREAST CANCER IN ECUADOR
    Cabezas, M.
    Freire, V
    Salcedo, E.
    Albert, A.
    VALUE IN HEALTH, 2018, 21 : S32 - S32
  • [42] Pirfenidone inhibits CCL2-mediated Treg chemotaxis induced by palbociclib and fulvestrant in HR+/HER2-breast cancer
    Li, Siwei
    Zhang, Xianyu
    Pang, Da
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 142
  • [43] Gain of HER2 Amplification in Patients with HR+/HER2-and Triple Negative Early Breast Cancer Treated with Neoadjuvant Chemotherapy
    Ferraro, Emanuela
    Minmin, Sonya Chew
    Safonov, Anton
    Barrio, Andrea V.
    Modi, Shanu
    Seidman, Andrew D.
    Wen, Hanna Y.
    Brogi, Edi
    Robson, Mark E.
    Dang, Chau T.
    CANCER RESEARCH, 2023, 83 (05)
  • [44] Current trends in the treatment of HR+/HER2+breast cancer
    Kay, Charlene
    Martinez-Perez, Carlos
    Meehan, James
    Gray, Mark
    Webber, Victoria
    Dixon, J. Michael
    Turnbull, Arran K.
    FUTURE ONCOLOGY, 2021, 17 (13) : 1665 - 1681
  • [45] Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2-metastatic breast cancer
    Robert, Nicholas
    Chen, Connie
    Kim, Sindy
    Zhang, Zhe
    Aguilar, Kathleen M.
    Wang, Yunfei
    Li, Benjamin
    Gaffney, Michael
    Huang, Xin
    Mcroy, Lynn
    FUTURE ONCOLOGY, 2024, 20 (12) : 761 - 780
  • [46] Palbociclib plus endocrine therapy in HR+/HER2-advanced breast cancer patients: Interim results of the PERFORM study
    Radosa, J. C.
    Fietz, T.
    Wilke, J.
    Decker, T.
    Petersen, V.
    Deryal, M.
    Knoblich, J.
    Losem, C.
    Rhein, U.
    Schoettker, B.
    Wrobel, D.
    Pfeiler, G.
    Zanucco, E.
    Buncke, J.
    Woerner, S.
    Gratzke, K.
    Adams, A.
    Glastetter, E.
    Bartsch, R.
    Lux, M. P.
    ANNALS OF ONCOLOGY, 2023, 34 : S353 - S354
  • [47] Tucatinib, palbociclib, and letrozole in HR+/HER2+metastatic breast cancer: Report of phase IB safety cohort.
    Shagisultanova, Elena
    Chalasani, Pavani
    Brown-Glaberman, Ursa Abigail
    Gradishar, William John
    Brenner, Andrew Jacob
    Stopeck, Alison
    Gao, Dexiang
    McSpadden, Tessa
    Kabos, Peter
    Borges, Virginia F.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] COST-EFFECTIVENESS ANALYSIS OF PALBOCICLIB FOR THE TREATMENT OF PATIENTS WITH HR+/HER2-ADVANCED/METASTATIC BREAST CANCER IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Mitova, R.
    Velchev, M.
    Vekov, T.
    VALUE IN HEALTH, 2018, 21 : S31 - S31
  • [49] CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2-Metastatic Breast Cancer
    Guerrero-Zotano, Angel
    Belli, Stefania
    Zielinski, Christoph
    Gil-Gil, Miguel
    Fernandez-Serra, Antonio
    Ruiz-Borrego, Manuel
    Gil, Eva Maria Ciruelos
    Pascual, Javier
    Munoz-Mateu, Montserrat
    Bermejo, Begon
    Vila, Mireia Margeli
    Anton, Antonio
    Murillo, Laura
    Nissenbaum, Bella
    Liu, Yuan
    Herranz, Jesus
    Fernandez-Garcia, Daniel
    Caballero, Rosalia
    Lopez-Guerrero, Jose Antonio
    Bianco, Roberto
    Formisano, Luigi
    Turner, Nicholas
    Martin, Miguel
    CLINICAL CANCER RESEARCH, 2023, 29 (08) : 1557 - 1568
  • [50] Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
    Hope S. Rugo
    Peter Kabos
    J. Thad Beck
    Guy Jerusalem
    Hans Wildiers
    Elena Sevillano
    Luis Paz-Ares
    Michael J. Chisamore
    Sonya C. Chapman
    Anwar M. Hossain
    Yanyun Chen
    Sara M. Tolaney
    npj Breast Cancer, 8
12345